The Duke Human Vaccine Institute's Pandemic Preparedness programs seek to build upon our world-class expertise in pandemic preparedness training, virology, immunology and CGMP manufacturing to strengthen our national response to future pandemic emergencies. We are taking a holistic approach to include pandemic preparedness training to improve and provide occupational training to those who may be exposed to infectious diseases and rapid development of pathogen-specific countermeasures to be deployed in a pandemic emergency. The DHVI Pandemic Preparedness programs include the Duke DARPA Pandemic Prevent Platform (P3) program and the Duke Infectious Diseases Response Training (DIDRT) .
In response to the anthrax attacks of 2001, the NIAID/NIH funded construction of 12 Regional Biocontainment Laboratories (RBLs) with two mandates:
- Provide state-of-the-art containment space to support research on drugs, diagnostics and vaccines against biological threats and emerging infections
- Support local and national responses to infectious disease emergencies.
RBLs were strategically constructed at major academic medical centers to create a broad research and response-training network. The Duke RBL facility in the DHVI is the home of the two Pandemic Preparedness programs: DIDRT and P3.
Related News
DHVI Receives Contract to Manufacture Investigational Avian Flu Vaccines
The Duke Human Vaccine Institute received funding from the National Institute of Allergy and Infectious Diseases (NIAID), a branch of the National Institutes of Health, to manufacture H5N1 avian flu vaccines for use in clinical trials.
NIAID recently funded $7 million to Duke under the contract called the Collaborative Influenza Vaccine Innovation Centers (CIVICs), which NIAID set up to develop new influenza vaccines that induce long-lasting immunity and protect against more variants of the virus.
Duke Health Leads Its First Clinical Trial Testing a New Universal Flu Vaccine
Duke Health is leading its first clinical trial under a large federal initiative to develop a new-generation flu vaccine.
Thomas Denny: Overseeing Duke's Vaccine Research Enterprise
As chief operating officer at the Duke Human Vaccine Institute (DHVI), Thomas Denny is in the unique position of helping people fight flu and HIV, developing the next generation of COVID-19 vaccines, and all the while leading an annual $120 million enterprise.
Duke Human Vaccine Institute to Serve as National Coordinating Center in Fight Against Influenza, COVID-19 and Respiratory Viruses
DHVI receives $4.9 million grant from CDC to serve seven U.S. sites
